Clinical trials
Fatty Liver clinical trials
Below are recruiting fatty liver clinical trials, each written for real people, not researchers. We’re tracking 166 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05554224Recruiting
Personalized treatment based on obesity-related fatty liver tests
This study uses multiple types of health data (“multi-omics”) to help choose a personalized treatment plan for people with obesity-related fatty liver disease. It may help match treatment to your biology to improve outcomes.
Reus, TarragonaAges 18 years+ - NCT06704321Recruiting
Effects of TOTUM-448 on liver fat and heart health
This trial tests a supplement called TOTUM-448 to see if it can reduce liver fat and improve heart health in people with a fatty liver condition (MASLD). If you have excess liver fat and are overweight, this study could help find new ways to manage your condition.
Québec, QuebecAges 18–75 - NCT05439226Recruiting
Diet plan targeting liver fat for type 2 diabetes
This study tests whether a Chinese medical nutrition therapy diet can reduce liver fat and help manage type 2 diabetes in people who also have fatty liver. You may be asked to follow a specific eating plan and keep your diabetes care stable during the study.
Yichang, HubeiAges 18–75 - NCT07086989Recruiting
Heart health study for kids with chronic conditions
This study looks at heart disease risk in children and young adults (ages 6-25) with long-term health conditions like certain heart, kidney, or diabetes disorders. The goal is to better understand and manage heart risks early.
BudapestAges 6–25 - NCT07632677Recruiting
Testing a liver inflammation score in diabetes and fatty liver
This study tests whether a new scoring method can help doctors identify liver inflammation in patients who have both type 2 diabetes and a fatty liver. The goal is to find an easier, safer way to assess liver health without invasive procedures.
Bengbu, AnhuiAges 18 years+ - NCT03481829Recruiting
Long-term study tracking health factors from pregnancy
This study follows pregnant mothers and their babies for years to understand how early life factors can affect health later. If you qualify, you and your child(ren) will be asked to stay in the research study for at least 3 years after delivery.
Phoenix, ArizonaAges 1 day–99 years - NCT00575133Recruiting
Study of people with fatty liver disease
This study follows people who have been confirmed to have fatty liver disease seen on a liver sample. It aims to understand the condition over time and how different causes and health factors may affect it.
Zurich, Canton of ZurichAges 18 years+ - NCT01403402Recruiting
Study of congenital muscle disease patients and their families
This trial collects health information from patients with certain inherited (genetic) muscle diseases and from their families. It may help researchers better understand the disease and improve care by learning what symptoms and treatments patients experience over time.
Lakewood, CaliforniaAges Any age - NCT05255978Recruiting
Follow-up study for hepatitis B with fatty liver
This observational study looks at people with chronic hepatitis B who also have fatty liver (non-alcoholic fatty liver disease). It follows how their liver health changes over time and may help doctors understand outcomes and risk factors.
Wuhan, HubeiAges 18 years+ - NCT05546086Recruiting
Beijing health study for adults who live in Beijing
This study collects health information from adults (18+) who are permanent residents of Beijing. It aims to learn patterns about health in the local population and how different factors may affect outcomes over time.
BeijingAges 18 years+ - NCT05597709Recruiting
Study diabetes patients to measure MAFLD in Jiangsu
This study checks how common a condition called MAFLD is among people with type 2 diabetes in Jiangsu, China. It may help doctors understand how often this liver-related problem occurs and guide future care for people with type 2 diabetes.
Nanjing, JiangsuAges 18 years+ - NCT05625750Recruiting
Study of people diagnosed with fatty liver from not-too-much alcohol
This is an observational study for people diagnosed with nonalcoholic fatty liver disease (fatty buildup in the liver not mainly caused by heavy drinking). It may help researchers better understand this condition, especially how it shows up on tests and how people report relevant health information.
Changsha, HunanAges 18–75 - NCT05766449Recruiting
Study of liver inflammation and scarring in hepatitis B or fatty liver
This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.
NanjingAges 18 years+ - NCT05046483Recruiting
Blood sugar study after a new heart attack
This study measures how your body handles sugar and related hormones in people after a new STEMI heart attack, and compares them with people who do not have diabetes or have prediabetes. The goal is to better understand metabolic changes after the event, which could help future care.
Düsseldorf, North Rhine-WestphaliaAges 18–80 - NCT06061042Recruiting
Time-restricted eating for metabolic health
This study tests whether eating only during a specific time window each day can improve metabolic health in people with obesity and insulin resistance. If you have a high BMI and early signs of diabetes, this trial might help you understand a simple dietary change.
Amsterdam, North HollandAges 50–75 - NCT06115876Recruiting
Kuwait diabetes long-term follow-up study
This study checks in on people with prediabetes or type 2 diabetes who were part of an earlier Kuwait diabetes study. It aims to understand how their condition has changed and what health care they may need.
Kuwait CityAges 21–75 - NCT03811236Recruiting
Test cold exposure to activate body fat and reduce liver fat
This study tests whether controlled cold exposure can activate “brown fat” and affect liver fat buildup. It may help people with excess liver fat, measured on imaging, but it has several health and medication exclusions.
ViennaAges 18–50 - NCT03851627RecruitingPhase 4
Testosterone for fatty liver in overweight men with diabetes
This trial compares testosterone undecanoate versus a placebo (inactive pill) to see if it lowers fat in the liver measured by MRI. It focuses on overweight or obese men who have prediabetes or type 2 diabetes and low testosterone confirmed by blood tests.
ViennaAges 18–75 - NCT06449833RecruitingPhase 4
Henagliflozin for liver fat in diabetes and fatty liver
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
Guangzhou, GuangdongAges 18–75 - NCT07820800Recruiting
Personalized digital health guidance for middle-aged adults
This study tests whether a digital health app can help middle-aged adults based on their personal metabolic risk. It aims to prevent diseases by providing tailored guidance.
SavonlinnaAges 45–55 - NCT06203548Recruiting
Tracking liver fat with a continuous monitor
This study looks at a new way to track how much fat is in your liver using a simple, continuous device. It may help people with fatty liver disease and related metabolic issues (like being overweight or having high blood sugar) avoid frequent MRI scans.
Hong KongAges 18–65 - NCT07726368RecruitingPhase 1
Study of ECC4703 with sulfasalazine and pitavastatin
This early-phase study tests how a new drug (ECC4703) works in the body when taken with two other common medications (sulfasalazine and pitavastatin). Healthy volunteers are needed to help researchers understand potential drug interactions and safety.
Melbourne, VictoriaAges 18–65 - NCT06211868Recruiting
Early heart disease risk study for adults 40-70
This study looks at whether changing your immune system, fats, and metabolism can lower your risk of early heart disease. It is for people with an intermediate to high risk score but who have not yet had a heart attack or stroke.
SingaporeAges 40–70 - NCT06649162Recruiting
Fatty liver risk in type 2 diabetes and new combo therapy
This study is looking at how often people with type 2 diabetes also have fatty liver disease, and whether a new combination medication (dapagliflozin and pioglitazone) can help manage both conditions.
Andong, Gyeongsangbuk-doAges 19 years+
Hear when a new Fatty Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fatty liver?
- Yes. Clin2 currently lists 166 recruiting fatty liver studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fatty liver trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fatty liver trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.